β-Glucan–mediated macrophage priming enhances macrophage activation and host defense against Mycobacterium tuberculosis infection
- 1Department of Physiological Sciences, Oklahoma Centre for Respiratory and Infectious Diseases, Oklahoma State University
- 2Department of Biosciences, Integral University
- 3Department of Life Sciences & Biotechnology, CSJM University
Abstract
Tuberculosis remains a major cause of infectious mortality worldwide, highlighting the need for complementary therapeutic strategies beyond conventional antibiotics. Host-directed approaches may enhance macrophage-mediated control of infection. In this study, we investigated the effects of β-glucan priming combined with drug-loaded yeast-derived β-glucan particles (DYDGP) in an in vitro macrophage model of Mycobacterium tuberculosis infection. Phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages were compared across unprimed, β-glucan-only, antibiotic-only, and β-glucan-primed/DYDGP-treated groups. β-Glucan priming combined with DYDGP treatment was associated with enhanced receptor-mediated phagocytic activity, improved intracellular bacterial control, and preserved macrophage integrity. These effects were associated with increased intracellular reactive oxygen species (ROS) production, enhanced phagolysosomal maturation, and altered autophagic activity. Colony-forming unit (CFU) analysis showed that β-glucan-primed macrophages treated with DYDGP exhibited a significantly lower bacterial burden than the unprimed, β-glucan-only, and antibiotic-only groups at 1, 6, and 24 h post-infection. Unprimed macrophages showed progressive bacterial growth, with log CFU values of 4.2, 4.8, and 5.2, whereas β-glucan-primed/DYDGP-treated macrophages showed reduced values of 3.3, 2.5, and 2.1, respectively. β-Glucan-only treatment resulted in log CFU values of 4.2, 4.4, and 4.7, while antibiotic-only treatment resulted in values of 4.2, 4.1, and 3.9 at the corresponding time points. These findings suggest that β-glucan priming combined with DYDGP treatment may enhance intracellular control of M. tuberculosis in this macrophage model and support further investigation of this approach as a potential adjunctive strategy for tuberculosis.
Related
- Case Report: Analysis of antimicrobial therapy and pharmaceutical care of mixed Aspergillus and Mycobacterium tuberculosis infection following renal transplantation: a case study
- ACE2 Polymorphisms rs2285666 and rs147311723 Are Clinically Relevant Variants in SARS-CoV-2 and Mycobacterium tuberculosis Co-infection.
- Galectin-3 recruitment at the Mycobacterium tuberculosis -containing phagosome is critical in macrophage but dispensable in epithelial cells
- Differential formation of nitrate-responsive mycobacterial intracytoplasmic membranes during Mycobacterium tuberculosis infection
- Defense and subversion: multilevel mitochondrial quality control and pathway‑specific mitophagy outcomes in Mycobacterium tuberculosis infection
BibTeX
@article{ahmad2026βglucanmediated,
title = {{β-Glucan–mediated macrophage priming enhances macrophage activation and host defense against Mycobacterium tuberculosis infection}},
author = {Firoz Ahmad and Mohd Khubaib and Rolee Sharma},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1952695},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1952695/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - β-Glucan–mediated macrophage priming enhances macrophage activation and host defense against Mycobacterium tuberculosis infection
AU - Firoz Ahmad
AU - Mohd Khubaib
AU - Rolee Sharma
PY - 2026
DA - 2026/10/09
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1952695
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1952695/full
AB - Tuberculosis remains a major cause of infectious mortality worldwide, highlighting the need for complementary therapeutic strategies beyond conventional antibiotics. Host-directed approaches may enhance macrophage-mediated control of infection. In this study, we investigated the effects of β-glucan priming combined with drug-loaded yeast-derived β-glucan particles (DYDGP) in an in vitro macrophage model of Mycobacterium tuberculosis infection. Phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages were compared across unprimed, β-glucan-only, antibiotic-only, and β-glucan-primed/DYDGP-treated groups. β-Glucan priming combined with DYDGP treatment was associated with enhanced receptor-mediated phagocytic activity, improved intracellular bacterial control, and preserved macrophage integrity. These effects were associated with increased intracellular reactive oxygen species (ROS) production, enhanced phagolysosomal maturation, and altered autophagic activity. Colony-forming unit (CFU) analysis showed that β-glucan-primed macrophages treated with DYDGP exhibited a significantly lower bacterial burden than the unprimed, β-glucan-only, and antibiotic-only groups at 1, 6, and 24 h post-infection. Unprimed macrophages showed progressive bacterial growth, with log CFU values of 4.2, 4.8, and 5.2, whereas β-glucan-primed/DYDGP-treated macrophages showed reduced values of 3.3, 2.5, and 2.1, respectively. β-Glucan-only treatment resulted in log CFU values of 4.2, 4.4, and 4.7, while antibiotic-only treatment resulted in values of 4.2, 4.1, and 3.9 at the corresponding time points. These findings suggest that β-glucan priming combined with DYDGP treatment may enhance intracellular control of M. tuberculosis in this macrophage model and support further investigation of this approach as a potential adjunctive strategy for tuberculosis.
SN - 1664-302X
ER -